AU2001286918B2 - ErbB4 antagonists - Google Patents

ErbB4 antagonists Download PDF

Info

Publication number
AU2001286918B2
AU2001286918B2 AU2001286918A AU2001286918A AU2001286918B2 AU 2001286918 B2 AU2001286918 B2 AU 2001286918B2 AU 2001286918 A AU2001286918 A AU 2001286918A AU 2001286918 A AU2001286918 A AU 2001286918A AU 2001286918 B2 AU2001286918 B2 AU 2001286918B2
Authority
AU
Australia
Prior art keywords
erbb4
antibody
receptor
accession number
smooth muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001286918A
Other languages
English (en)
Other versions
AU2001286918A1 (en
Inventor
Mary E. Gerritsen
Mark X. Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001286918A1 publication Critical patent/AU2001286918A1/en
Application granted granted Critical
Publication of AU2001286918B2 publication Critical patent/AU2001286918B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2001286918A 2000-09-01 2001-08-29 ErbB4 antagonists Ceased AU2001286918B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22967900P 2000-09-01 2000-09-01
US60/229,679 2000-09-01
US26551601P 2001-01-31 2001-01-31
US60/265,516 2001-01-31
US09/940,101 2001-08-27
US09/940,101 US20020119148A1 (en) 2000-09-01 2001-08-27 ErbB4 antagonists
PCT/US2001/026984 WO2002018444A2 (en) 2000-09-01 2001-08-29 Erbb4 antagonists

Publications (2)

Publication Number Publication Date
AU2001286918A1 AU2001286918A1 (en) 2002-06-06
AU2001286918B2 true AU2001286918B2 (en) 2006-12-21

Family

ID=27397993

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001286918A Ceased AU2001286918B2 (en) 2000-09-01 2001-08-29 ErbB4 antagonists
AU8691801A Pending AU8691801A (en) 2000-09-01 2001-08-29 Erbb4 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8691801A Pending AU8691801A (en) 2000-09-01 2001-08-29 Erbb4 antagonists

Country Status (11)

Country Link
US (6) US20020119148A1 (https=)
EP (1) EP1351744B1 (https=)
JP (1) JP2004507559A (https=)
AT (1) ATE374642T1 (https=)
AU (2) AU2001286918B2 (https=)
CA (1) CA2420062C (https=)
DE (1) DE60130797T2 (https=)
DK (1) DK1351744T3 (https=)
ES (1) ES2295202T3 (https=)
IL (2) IL154495A0 (https=)
WO (1) WO2002018444A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
JP4527388B2 (ja) * 2003-12-11 2010-08-18 東洋鋼鈑株式会社 ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101495503A (zh) * 2005-03-07 2009-07-29 塔盖替德分子诊断有限公司 酪氨酸激酶抑制剂组合物及其制造方法和在疾病治疗中的应用
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
CN102725310A (zh) 2008-11-25 2012-10-10 健泰科生物技术公司 同等型特异性抗her4抗体
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
US9725511B2 (en) * 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
FR3020063A1 (fr) * 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US12577324B2 (en) * 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015128A2 (en) * 1994-11-14 1996-05-23 Warner-Lambert Company 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
EP0950067B1 (en) * 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6994856B1 (en) * 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CA2412377A1 (en) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015128A2 (en) * 1994-11-14 1996-05-23 Warner-Lambert Company 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Biol Chem vol 271 no 13 1996 pp 7620-7629 *
J Biol Chem vol 274 no 13 1999 pp 8624-8629 *

Also Published As

Publication number Publication date
IL154495A0 (en) 2003-09-17
DE60130797T2 (de) 2008-08-07
DK1351744T3 (da) 2008-02-11
US20020119148A1 (en) 2002-08-29
US20090068205A1 (en) 2009-03-12
WO2002018444A3 (en) 2003-07-31
HK1059404A1 (en) 2004-07-02
EP1351744B1 (en) 2007-10-03
US7332579B2 (en) 2008-02-19
CA2420062C (en) 2014-04-01
WO2002018444A2 (en) 2002-03-07
DE60130797D1 (de) 2007-11-15
US7704498B2 (en) 2010-04-27
ES2295202T3 (es) 2008-04-16
JP2004507559A (ja) 2004-03-11
IL154495A (en) 2009-12-24
US20060093603A1 (en) 2006-05-04
US20100190964A1 (en) 2010-07-29
ATE374642T1 (de) 2007-10-15
US20070092513A1 (en) 2007-04-26
AU8691801A (en) 2002-03-13
CA2420062A1 (en) 2002-03-07
US20040052786A1 (en) 2004-03-18
EP1351744A2 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
AU2001286918B2 (en) ErbB4 antagonists
AU2001286918A1 (en) ErbB4 antagonists
AU705107B2 (en) HTK ligand
CA2185656C (en) Protein tyrosine kinase agonist antibodies
US5667780A (en) Antibodies to SMDF
DE69936382T2 (de) Therapeutische verwendungen von il-17 homologe polypeptide
ES2206448T3 (es) Heregulinas (hrgs), proteinas de union de p185?erb2.
KR101078459B1 (ko) 항 수초 관련 당단백질 항체
US20050084493A1 (en) Screening method for antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
NZ333325A (en) Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors
CA2241564A1 (en) Wsx receptor and ligands
JP2015108015A (ja) Ｉｌ−１７ａ／ｆヘテロ二量体ポリペプチドおよびその治療上の使用
JP2002530066A (ja) Ｒｈａｍｍアンタゴニスト抗体
CA2422953A1 (en) Identification and modification of immunodominant epitopes in polypeptides
HK1059404B (en) Use of specific erbb4 antagonists for treating stenosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired